Anti-Depressants for Mental Disorder: 50.0% of denials overturned
In 94 California IMR decisions from 2007 to 2025, reviewers overturned 47 (50.0%). In the last five years: 48.8% of 41. 86 were medical-necessity disputes, 8 experimental/investigational.
By year (last five)
| Year | Decisions | Overturned |
|---|---|---|
| 2021 | 7 | 42.9% |
| 2022 | 7 | 42.9% |
| 2023 | 10 | 50.0% |
| 2024 | 5 | 20.0% |
| 2025 | 12 | 66.7% |
What the findings mention
| What the findings mention | Decisions | Overturned | All decisions here |
|---|---|---|---|
| Published evidence citedThe findings refer to peer-reviewed or published evidence. | 27 | 48.1% | 50.0% |
| Prior therapies failedThe findings mention treatments that were tried without adequate response. | 25 | 48.0% | 50.0% |
| Records did not supportThe findings say the documentation did not show what was needed (usually an upheld denial). | 16 | 12.5% | 50.0% |
| FDA approval or off-label use discussedThe findings discuss the FDA label status of the treatment. | 10 | 30.0% | 50.0% |
| Guidelines or criteria citedThe findings cite guidelines, criteria or a standard of care. | 8 | 50.0% | 50.0% |
| Alternatives contraindicatedThe findings mention a contraindication to the plan's preferred option. | 3 | 66.7% | 50.0% |
Keyword matches on the reviewer’s findings, not causes. A tag that appears mostly in overturned decisions is worth documenting in an appeal; it is not a guarantee.
From recent overturned decisions
“The physician reviewer found that Nature of Statutory Criteria/Case Summary:A patient has requested authorization and coverage for an increased frequency of esketamine therapy. Esketamine is an FDA-approved treatment for treatment-resistant depression, with dosing individualized based on clinical response. Clinical guidelines support adjustment of dosing frequency in patients who demonstrate worsening symptoms when treatment is reduced. In this case, the patient …”
“The physician reviewer found that Nature of Statutory Criteria/Case Summary:A patient has requested reimbursement and prospective authorization and coverage for an increase in dosing frequency of esketamine therapy. Esketamine is an FDA-approved treatment for treatment-resistant depression, with dosing schedules individualized based on clinical response. Clinical guidelines and medical literature support adjustments in dosing frequency for patients who have shown partial …”
“The physician reviewer found that Nature of Statutory Criteria/Case Summary:A patient has requested authorization and coverage for Spravato. Spravato is a U.S. Food and Drug Administration (FDA)-approved treatment for patients with treatment-resistant depression. Clinical guidelines and medical literature support its use in individuals who have not responded adequately to multiple prior antidepressant therapies. In this case, the patient has severe, …”
And one the reviewer upheld
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for intravenous ketamine therapy. The patient has a history of major depressive disorder and post-traumatic stress disorder. The medical records indicate failure of multiple evidence-based treatments, including numerous psychotropic medications, transcranial magnetic stimulation, and electroconvulsive therapy. The records further note that the patient …”
- California only: these are decisions by independent reviewers under California's IMR program (plans regulated by the Department of Managed Health Care). Other states and self-funded employer plans use different reviewers and rules.
- Selection: only denials that a member took all the way to IMR appear. Most denials are never appealed, and the ones that reach an external reviewer are not a random sample.
- Overturned means the reviewer disagreed with the plan; it does not mean the treatment worked or that a similar request will be approved.
- Argument tags are keyword matches on the reviewer's findings. They describe what the findings mention, not why the case was decided.
- Categories are DMHC's own labels (treatment sub-category and diagnosis category); 'Other' is a catch-all and is excluded from rankings.
Source: California Department of Managed Health Care, Independent Medical Review (IMR) Determinations, Trend (CHHS Open Data). Public California government data; Apellica's aggregates and tags are CC BY 4.0.
Questions
How often were Anti-Depressants denials for Mental Disorder overturned?
In 94 California IMR decisions from 2007 to 2025, reviewers overturned 47 (50.0%). In the last five years: 48.8% of 41. 86 were medical-necessity disputes, 8 experimental/investigational.
What should an appeal document, based on these findings?
Whatever the plan's criteria ask for, shown in the record: the treatments already tried and their results, contraindications to the plan's preferred option, the guideline or evidence that supports the request, and the treating clinician's reasoning written to the criteria. The tag table shows which of these the reviewers mentioned most in overturned cases.
Does a California IMR result apply to my plan?
Only California plans regulated by the Department of Managed Health Care go to IMR. Other states and self-funded employer plans use different reviewers, but they weigh the same things.
Independent reviewers reverse plans when the record answers the criteria. Upload the denial letter; a senior reviewer reads it within 24 hours and tells you in writing whether it can be appealed and how. $0 upfront, 10% of what is recovered, nothing if we do not recover. Not a law firm.